Advanced NSCLC: CNS Penetration With Novel EGFR TKI Therapy

Video

A brief review of novel EGFR TKIs that may have stronger CNS penetration in patients with non–small cell lung cancer and brain metastases.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
2 experts in this video
2 experts in this video
Related Content
Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care

Russ Conroy
September 16th 2025
Article
1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
September 16th 2025
Podcast
An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

VT3989 Receives Orphan Drug Designation for the Treatment of Mesothelioma

Roman Fabbricatore
September 16th 2025
Article
1 expert in this video

CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer

Alvaro A. Martinez, MD
September 16th 2025
Podcast
A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.

COCOON Regimen Shows Promise in Mitigating Dermatologic AEs During NSCLC Treatment

ONCOLOGY Staff
September 16th 2025
Article
The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

ONCOLOGY Staff
September 16th 2025
Article